ISSN 1308-8734 | E-ISSN 1308-8742
Review
Mycophenolate Mofetil in the Treatment of Systemic Lupus Erythematosus
1 Ankara University, School of Medicine, Department of Clinical Immunology and Rheumatology, Ankara, Turkey.  
Eurasian J Med 2009; 41: 180-185

Key Words: Systemic lupus erythematosus, Mycophenolate mofetil, Treatment
Abstract

Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been shown to be effective in transplant patients. It is also efficacious in the management of lupus nephritis and useful in the treatment of autoimmune conditions because its mechanisms of action target T- and B- lymphocytes, leading to suppression of the cell-mediated immune response and antibody formation. MMF has been used successfully to treat immune-mediated conditions like myasthenia gravis, autoimmune hepatitis and immune cytopenias. However, the conditions for its optimal use for non-renal manifestations (e.g., hematological, neuropsychiatric, myocardial, pulmonary or cutaneous symptoms) in lupus patients are unclear. There have yet to be any randomized, controlled trials to guide the optimal dose and duration of MMF treatment in such situations. MMF is well tolerated and safe to use, although there are reports of serious adverse effects including urticaria, myopathy, Epstein-Barr virus-associated Bcell lymphoma, cytomegalovirus infection and disseminated varicella zoster infection. Immunosuppressive treatment with MMF and supportive care over the past few decades have led to improved clinical outcomes in patients with severe lupus nephritis. A favorable longterm prognosis can be ensured provided that effective treatment is instituted early, before irreversible renal parenchymal damage occurs. Another area of concern for patients is the increased cost of long-term MMF use.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2017 Atatürk University Faculty of Medicine | Latest Update: 24.10.2017